Articles by Cecilia Brown
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Dr. Ghobrial discusses how she entered the field of smoldering myeloma, the racial gap in myeloma research, and more.
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
The study enrolled 214 participants, including 111 patients with 39 different RUNX1 variants from 45 unrelated families.
Dr. Garcia-Manero said he hopes to find “better treatments” and even “one day a cure for this condition.”
Researchers found that 16% of the patients analyzed had pre-existing autoimmune disease.
Across the entire study population, the two most frequent U2AF1 variants were S34F (n=97) and Q157P (n=46).
The rate of grade 3-5 infections was 90% lower in MM patients receiving IV immunoglobulin than during the observation period.
Researchers used a classification approach derived from machine learning to stratify patients into two subgroups.
The combination was previously “found to be well tolerated with an early signal of efficacy in a phase Ib study.”
The subcutaneous T-cell engaging bispecific antibody is now approved for the treatment of this patient population in the EU.
The study included 815 patients with AML who were “unfit to receive intensive induction chemotherapy."
Mutations in IDH were “strongly correlated with increased age,” according to the study’s authors.
The pooled ORR was 97% and the pooled complete remission rate was 93% in patients with ALL.
The study included 255 patients aged one to 30 years with low-risk first-relapse B-ALL.
Dr. Radich reflects on lessons in cowboy medicine, the genetics of luck, and a serendipitous meeting.
Researchers conducted a cross-sectional survey of patients with multiple myeloma to address the question.
The award was created in honor of Michael J. Keating, MD, a founding member and past president of SOHO.
Researchers evaluated 1,704 patients with triple-class exposure, including 1,072 who had four-plus previous lines of therapy.
RNA sequencing analysis revealed noncanonical function of BACH1 in regulation of type I interferon response.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.